Summary A mutation at codon 974 of the dihydropyrimidine dehydrogenase (DPD) gene was previously described in a cancer patient with undetectable DPD enzyme activity who experienced severe toxicity when treated with 5-fluorouracil. We have studied the frequency of this mutation in 29 Scottish subjects with low DPD enzyme activity and in 274 American subjects. We detected no mutations in the 606 alleles studied and conclude that mutations at codon 974 are a rare event.
The first and rate-limiting step in the catabolism of the pyrimidines uracil and thymine is carried out by the enzyme dihydropyrimidine dehydrogenase (DPD: EC 1.3.1.2). DPD enzyme activity has been detected in a number of human tissues, with the highest levels in the liver and lymphocytes (Naguib et al 1985) . Population studies have shown that enzyme activity has a unimodel distribution over a 7-to 14-fold range, with some individuals having very low or even undetectable levels (Lu et al 1993; Etienne et al 1994; McMurrough and McLeod 1996) . Low DPD activity is clinically important as such individuals can exhibit severe toxicity when treated with the anti-cancer agent 5-fluorouracil (5-FU) (Harris et al 1991; Houyau et al 1993) . In addition, total DPD deficiency is associated with the congenital syndrome thymine uraciluria (Meinsma et al 1995) . Population studies of DPD activity have suggested that the frequency of heterozygous and homozygous deficiency is 3% and 0.1% respectively . Two molecular alterations in the DPYD gene have been reported to date in patients with low enzyme activity. The deletion of a 165-bp exon has been demonstrated in a child with thymine uraciluria and in an adult who experienced near-fatal toxicity after receiving 5-FU therapy (Meinsma et al 1995; Wei et al 1996) . A point mutation at codon 974 (aspartic acid to valine) has been identified in a patient who experienced severe 5-FU-related toxicity (Harris et al 1991; Albin et al 1995) . The aspartic acid residue at codon 974 is not within the putative catalytic sites of the protein (Gonzalez and Fernandez-Salguero 1995) and the amino acid is conserved in the human, pig and cow sequences (GenBank/EMBL Accession numbers U09178, U09179 and U20981). The population frequency of these mutations is not known.
A polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) assay was used to study the prevalence of point mutations at codon 974 in two population cohorts. Initial studies were conducted in 29 Scottish blood donors with low DPD activity (19.1-69.3 pmol min-'mg-' protein), as measured using a high-performance liquid chromatography (HPLC)-based method for detecting radioactive metabolites (McMurrough and McLeod, 1996) . This represented the lowest 10% of a larger population study. DNA from 274 American black and white blood donors (Memphis, TN; McLeod et al, 1994) was also analysed, as these samples were collected from a region of geographical proximity to the originally reported case (Birmingham, AL; Harris et al, 1991; Albin et al, 1995) . DPD catalytic activity was not available for the American subjects.
MATERIALS AND METHODS PCR-RFLP analysis
The presence of a mutation at codon 974 was screened for using PCR to amplify a 238-bp fragment from genomic peripheral blood lymphocyte DNA using primers AspF2 (5'-CAATACCCTC-TATGTCTGTTTGC-3') and AspR2 (5'-GTAGGTGACAT-GAAAGATCACAG-3'). Reactions (50, l) were carried out in 50 mM potassium chloride 10 mM Tris-HCl, pH 9.0, 0.1% Triton X-100, 2.25 mM magnesium chloride, 0.8 mM dNTPs, 100 ng of each primer, 2.5 units Taq polymerase (Promega) and 100 ng genomic DNA. A control reaction with no DNA was also included. Amplification was carried out using 30 cycles of 95°C for 30 s, 58°C for 30 s and 72°C for 30 s. The presence of a mutation at codon 974 was detected by digesting 10 itl of each PCR sample with Mbol (in 10 mm Tris-HCl, pH 7.8, 10 mm magnesium chloride, 1 mm dithiothreitol) for 2 h at 37°C. The presence of a point mutation at codon 974 destroys an MboI site (GATC to GTTC). There was also an MboI site present in primer AspR2 (underlined and created by incorporating a single mismatched base at position 17 of the primer). The presence of this additional site provided a control for MboI activity in all digests. Digestion of the PCR fragment with MboI resulted in the production of three bands in wildtype samples ( . The digested products were analysed on a 2.5% agarose gel, which allowed the visualization of the 219-bp and 183-bp bands, which indicated the presence or absence of a mutation at codon 974 ( Figure 1 ). An additional control was created using primer AspF3 (5'-CAAT-ACCCTCTATGTCTGTTTGCAGGCTATACAGTTTGTTCCAG-3'), which incorporates a mutation at codon 974 that destroys the MboI site (underlined). Digestion of this product with MboI resulted in the formation of 219-bp and 19-bp fragments. A simulated heterozygote was created by mixing equal amounts of wildtype (Asp F2 and Asp R2) and mutant (Asp F3 and Asp R2) PCR products, heating the samples to 95°C and then digesting with MboI, as described above. These controls were run on each gel.
RESULTS AND DISCUSSION
No mutations were detected in the 303 samples (606 alleles) analysed, suggesting that the frequency of this mutation is low (< 0.2% of alleles). The lack of mutations in the 29 Scottish subjects with the lowest enzyme activity suggests that this mutation is not frequently associated with reduced DPD activity. The lower threshold of DPD activity identifying patients at risk of 5-FU toxicity is unclear, but has been suggested to be 100 pmol min-'mg-' protein, which is higher than the activity observed in the Scottish subjects studied . In addition, a number of patients with 5-FU-related toxicity have been described with DPD activity levels within the range of those studied here (Houyau et al, 1993; Takimoto et al, 1996) . However, it is possible that the mutation is only found in individuals with very low (<19.1 pmol min-'mg-' protein) or no detectable DPD activity, as described in the original proband for this mutation (Harris et al, 1991) . The absence of mutations in the 274 American subjects studied further suggests that these mutations are rare, even within a population of close geographical proximity to the originally described case. We conclude that mutations at codon 974 are rare and are present at a lower frequency than that estimated for cases of partial or complete DPD deficiency . This would indicate that other factors, including additional mutations, are also responsible for DPD deficiency.
